faah (rat)

Biochanin A (4-Methylgenistein) 是一种从红三叶车轴草中分离出来的异黄酮衍生物，具有抗癌特性。它是脂肪酸酰胺水解酶抑制剂，作用于小鼠、大鼠和人 FAAH，IC50分别为 1.8、1.4 和 2.4 μM。

JNJ-1661010 (Takeda-25) 是一种有效的、选择性的、可以穿透血脑屏障的脂肪酸酰胺水解酶 (FAAH) 抑制剂，对大鼠和人 FAAH 的 IC50分别为 34 和 33 nM，可用于缓解疼痛的研究。

BIA 10-2474 是一种长效可逆的脂肪酸酰胺水解酶抑制剂，与人类内源性大麻素系统相互作用，可增加中枢神经系统和外周组织，对大鼠大脑不同区域的 IC50值为50至70mg kg。它用于治疗焦虑症、帕金森氏病和多发性硬化症、高血压或肥胖症的慢性疼痛。

KML29 是一种口服具有活性的、高度选择性的不可逆 MAGL 抑制剂，其对小鼠、大鼠和人的 IC50值分别为15 nM、43 nM 和 5.9 nM。它对 FAAH 在内的其他中心和外周丝氨酸水解酶的交叉反应极小。

FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC50s of 145 nM and 650 nM for rat and human FAAH, respectively.

MK-3168 (12C) 作为一种FAAH抑制剂，对于人类、恒河猴和大鼠展现出了不同的IC50值，分别为1.0、5.5、1.7 nM。该化合物具有优异的脑部摄取能力及对FAAH的高特异性。另外，11C MK-3168 也适用于FAAH PET显像的示踪剂。

ASP8477是一种高效且选择性的FAAH抑制剂。该化合物通过口服活性能增加大脑中的阿纳米酰胺（anandamide）水平。在大鼠的神经病理性及骨关节炎疼痛模型中，ASP8477显示出良好的疗效，且不引起运动协调障碍。单次口服ASP8477能改善慢性压迫性神经损伤大鼠的热性痛觉过敏和寒冷痛觉异常。此外，ASP8477还能恢复由利血平引起的肌肉压力阈值下降的肌痛大鼠模型。研究表明，ASP8477在缓解神经病理性和功能性疼痛方面具有镇痛效果，其药理特性适合用于治疗慢性疼痛。

AZ513 是一种可逆的FAAH抑制剂，对人类FAAH和大鼠FAAH的IC50分别为551 nM和27 nM。AZ513 在转染人类FAAH的HEK293细胞中抑制花生四烯乙醇胺水解，IC50为360 nM。

JNJ-42165279 是一种 FAAH 抑制剂，抑制 hFAAH 和 rFAAH，IC50分别为70 ± 8 nM 和 313 ± 28 nM。它对其他酶、离子通道、转运蛋白和受体具有高度选择性。

URB754 is a potent and noncompetitive inhibitor of monoacylglycerol lipase (MAGL), exhibiting an IC50 value of 200 nM for the recombinant rat brain enzyme. However, it does not inhibit human recombinant, rat brain, or mouse brain MAGL at concentrations up to 100 μM. There is evidence that the MAGL inhibitory activity of URB754 may be attributed to the impurity bis(methylthio)mercurane (IC50 = 11.9 nM for rat recombinant MAGL) that is found in commercial preparations. URB754 inhibits rat brain fatty acyl amide hydrolase (FAAH) with an IC50 value of 32 μM and binds weakly to the rat central cannabinoid (CB1) receptor with an IC50 value of 3.8 μM. It does not inhibit COX-1 or COX-2 at concentrations up to 100 μM. Inhibition of MAGL hydrolysis of 2-arachidonoyl glycerol (2-AG) is associated with enhanced stress-induced analgesia and may represent a novel drug target in pain and stress management.

N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide binds to the cannabinoid 1 (CB1) receptor with a Ki value of 365 nM in a radioligand binding assay using rat brain homogenate. It has an EC50 value of 698 nM for the peroxisome proliferator-activated receptor α (PPARα) in a luciferase reporter assay and, in rats, it decreases food intake. It does not inhibit fatty acid amide hydrolase (FAAH).

PF-04457845 是一种非常有效的选择性 FAAH 抑制剂，作用于 rFAAH 和 hFAAH，IC50分别为 7.4±0.62 nM 和 7.2±0.63 nM。

JNJ-40413269 is a competitive inhibitor of fatty acid amide hydrolase (FAAH), which demonstrates robust central target engagement, and shows efficacious in a rat model of neuropathic pain.

Fatty acid amide hydrolase (FAAH), an enzyme responsible for the hydrolysis and inactivation of fatty acid amides like anandamide and oleamide, has been identified as a target by the potent FAAH inhibitor PHOP. PHOP demonstrates remarkable inhibitory activity with K_i values as low as 0.094 nM for human FAAH and 0.2 nM for rat FAAH. Additionally, through a proteomics assay focusing on the serine hydrolase enzyme family, to which FAAH belongs, PHOP's selectivity was evaluated, presenting IC_50 values of 1.1 nM against FAAH, 1.4 nM against triacylglycerol hydrolase (TGH), and greater than 100 µM against an uncharacterized hydrolase (KIAA1363). This specificity profile of PHOP underscores its potential for yielding precise outcomes in studies involving complex biological systems.

AKU-005 是一种针对FAAH和MAGL的双重抑制剂，其对大鼠FAAH和人类FAAH的抑制常数(IC50)分别为63 nM和389 nM。该化合物在探索三叉神经痛觉过敏方面显示出研究潜力。